A Phase I Study of Weekly Doxorubicin and Oral Topotecan for Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Doxorubicin (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- 16 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Sep 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.